Wechselwirkungen · Symkevi
Symkevi 50 mg/75 mg film-coated tablets Symkevi 100 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-140689 · Präparat HOS-098562
In vitro studies showed that tezacaftor is a substrate for the uptake transporter OATP1B1, and efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Tezacaftor is not a substrate for OATP1B3. Exposure to tezacaftor is not expected to be affected significantly by concomitant inhibitors of OATP1B1, P-gp, or BCRP due to its high intrinsic permeability and low likelihood of being excreted intact. However, exposure to M2-TEZ (tezacaftor metabolite) may be increased by inhibitors of P-gp. Therefore, caution should be used when P-gp inhibitors are used with Symkevi.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-08T13:35:00Z · SHA-256 e139cc35dca65a70a96b9c8a1ad8e556657e48aee661616c1f43437d6b315911 · Passage 60baf5c7da8a440a8768d0d2af0eb2cf6e69b3e90bbe00271566969d7bc68a19 · Zeichen 2056–2654 im Abschnitt